DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

被引：3
|
作者：
Yoon, Jee Sun
Kim, Jin Won
Kim, Ji-Won
Kim, Tae-Yong
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Oh, Kyoung Seok
Mortimer, Peter G.
Smith, Simon
Oh, Do-Youn
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] AstraZeneca, R&D Oncol, Early Oncol Clin Sci, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4166
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC
    Li Jingjing
    Xu, Qi
    Xu, Xiaoqing
    Cong, Luo
    Ying, Jieer
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).
    Tutt, Andrew
    Stephens, Christine
    Frewer, Paul
    Pierce, Andrew
    Rhee, Joon
    Edgington, Sarah
    Ottesen, Lone
    Ah-See, Mei-Lin
    Hollingsworth, Simon J.
    Dean, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
    Li, Jingjing
    Qi, Xu
    Wei, Qing
    Han, Zhe
    Cong, Luo
    Zhang, Fabiao
    Ying, Jieer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A PHASE 1B/2 UMBRELLA STUDY OF ANTI-PD-1 SASANLIMAB IN COMBINATION WITH OTHER THERAPIES FOR PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC): THE LANDSCAPE 1011 TRIAL IN PROGRESS
    Boyer, Michael
    Patel, Sandip
    Marron, Thomas
    Pavlakis, Nick
    Parakh, Sagun
    Gadgeel, Shirish
    Shafique, Michael
    Hoyer, Robert
    Camidge, D. Ross
    Farber, Charles
    Mehra, Ranee
    Mekhail, Tarek
    Blinman, Prunella
    Kowalski, Karey
    Davis, Craig
    Pavlov, Dmitri
    Gad, Nayra
    Massarelli, Erminia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A484 - A484
  • [45] ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)
    Zelnak, Amelia B.
    Lenz, Heinz-Josef
    Culm, Kerry
    Makris, Lukas
    Santos, Valerie Chamberlain
    Youssoufian, Hagop
    Mockbee, Colleen
    Miller, Kathy D.
    CANCER RESEARCH, 2023, 83 (05)
  • [46] NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
    Yap, Timothy A.
    Dumbrava, Ecaterina E.
    Ahnert, Jordi Rodon
    Tsimberidou, Apostolia M.
    Hong, David
    Piha-Paul, Sarina A.
    Karp, Daniel D.
    Fu, Siqing
    Naing, Aung
    Pohlmann, Paula
    Rhudy, Jessica R.
    Berenji-Jalaei, Sheila B.
    Cole, Ashley A.
    Valladolid, Christian
    Dufner, Desirae
    Bockorny, Bruno B.
    Bullock, Andrea
    Fein, Daniel
    Buchbinder, Elizabeth
    Choudhury, Atish
    Haddox, Candace
    Lee, Elizabeth
    Wulf, Gerburg
    Ivy, Percy
    Said, Rabih
    Shapiro, Geoffrey
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (07)
  • [47] VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes
    Tutt, Andrew
    Stephens, Christine
    Frewer, Paul
    Pierce, Andrew
    Rhee, Joon
    So, Karen
    Ottesen, Lone
    Dean, Emma
    Hollingsworth, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Han, Hyunsil
    Casey, Kerry A.
    Li, Siyu
    Ganguly, Samit
    Seebach, Frank A.
    Mathias, Melissa Divya
    Pelster, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS239 - TPS239
  • [49] BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis
    O'Kane, Grainne M.
    Spratlin, Jennifer L.
    Oh, Do-Youn
    Rha, Sun Young
    Elimova, Elena
    Kavan, Petr
    Choi, Moon Ki
    Goodwin, Rachel Anne
    Kim, Seung Tae
    Koo, Dong-Hoe
    Halani, Khalif
    McAllister, E. Russell
    Jones, Michelle
    Snow, Malcolm
    Lemmerick, Yasmin
    Spera, Gonzalo
    Pankovich, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
    Seery, Tara Elisabeth
    Nangia, Chaitali Singh
    Sender, Leonard S.
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345